Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective US chart review.

被引：0
|
作者：
Yang, Hongbo
Wong, Michael K. K.
Signorovitch, James E.
Wang, Xufang
Liu, Zhimei
Liu, Nathan S.
Qi, Zhengyun
George, Daniel J.
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[3] Novartis Pharmaceut, Florham Pk, NJ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4612
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review
    Wong, Michael K.
    Yang, Hongbo
    Signorovitch, James E.
    Wang, Xufang
    Liu, Zhimei
    Liu, Nathan S.
    Qi, Cynthia Z.
    George, Daniel J.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (04) : 537 - 545
  • [2] Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review
    Vogelzang, Nicholas J.
    Pal, Sumanta K.
    Signorovitch, James E.
    Reichmann, William M.
    Li, Nanxin
    Yang, Chelsey
    Liu, Zhimei
    Perez, Jose Ricardo
    Jonasch, Eric
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (04) : 741 - 747
  • [3] More Than 4 Years of Progression-free Survival in a Patient with Metastatic Renal Cell Carcinoma Treated Sequentially with Sunitinib, Everolimus, Sorafenib, and Temsirolimus
    Oudard, Stephane
    [J]. ANTICANCER RESEARCH, 2010, 30 (12) : 5223 - 5225
  • [4] Progression-Free Survival as a Predictor of Overall Survival in Metastatic Renal Cell Carcinoma Treated With Contemporary Targeted Therapy
    Heng, Daniel Y. C.
    Xie, Wanling
    Bjarnason, Georg A.
    Vaishampayan, Ulka
    Tan, Min-Han
    Knox, Jennifer
    Donskov, Frede
    Wood, Lori
    Kollmannsberger, Christian
    Rini, Brian I.
    Choueiri, Toni K.
    [J]. CANCER, 2011, 117 (12) : 2637 - 2642
  • [5] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
    Verzoni, Elena
    Iacovelli, Roberto
    Rizzo, Mimma
    Felici, Alessandra
    Cascinu, Stefano
    Di Lorenzo, Giuseppe
    Cerbone, Linda
    Ortega, Cinzia
    Masini, Cristina
    Giganti, Maria Olga
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Tassi, Renato
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [6] Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer
    Uhlig, Annemarie
    Uhlig, Johannes
    Trojan, Lutz
    Woike, Michael
    Leitsmann, Marianne
    Strauss, Arne
    [J]. FUTURE ONCOLOGY, 2021, 17 (01) : 45 - 56
  • [7] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    [J]. CANCER, 2014, 120 (01) : 52 - 60
  • [8] Cost per month of overall survival and progression-free survival: everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma
    Swallow, Elyse
    Ghate, Sameer
    Messali, Andrew
    Mcdonald, Evangeline
    Duchesneau, Emilie
    Perez, Jose R.
    [J]. BJU INTERNATIONAL, 2016, 118 : 17 - 18
  • [9] Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US
    Pal, Sumanta K.
    Jonasch, Eric
    Signorovitch, James E.
    Reichmann, William M.
    Li, Nanxin
    Liu, Zhimei
    Perez, Jose Ricardo
    Vogelzang, Nicholas J.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (05) : 462 - 468
  • [10] Everolimus Versus Temsirolimus in Metastatic Renal Cell Carcinoma After Progression With Previous Systemic Therapies
    Patel, Shiven B.
    Stenehjem, David D.
    Gill, David M.
    Tantravahi, Srinivas K.
    Agarwal, Archana M.
    Hsu, JoAnne
    Vuong, Winston
    Pal, Sumanta K.
    Agarwal, Neeraj
    [J]. CLINICAL GENITOURINARY CANCER, 2016, 14 (02) : 153 - 159
12345